Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

被引：88

作者：

Hochmair, Maximilian J. ^{[1
]}

Morabito, Alessandro ^{[2
]}

Hao, Desiree ^{[3
]}

Yang, Cheng-Ta ^{[4
]}

Soo, Ross A. ^{[5
]}

Yang, James C-H ^{[6
,7
]}

Gucalp, Rasim ^{[8
]}

Halmos, Balazs ^{[8
]}

Wang, Lara ^{[9
]}

Golembesky, Amanda ^{[10
]}

Maerten, Angela ^{[11
]}

Cufer, Tanja ^{[12
]}

机构：

[1] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Dept Resp & Crit Care Med, Sanatoriumstr 2, A-1140 Vienna, Austria

[2] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, I-80131 Naples, Italy

[3] Univ Calgary, Cummings Sch Med, Tom Baker Canc Ctr, Calgary, AB, Canada

[4] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[5] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[8] Montefiore Albert Einstein, Canc Ctr, Dept Oncol, Bronx, NY USA

[9] Boehringer Ingelheim Taiwan Ltd, Clin Trials, Taipei, Taiwan

[10] Boehringer Ingelheim Int GmbH, Epidemiol, Ingelheim, Germany

[11] Boehringer Ingelheim Int GmbH, Med Affairs Oncol, Ingelheim, Germany

[12] Univ Ljubljana, Univ Clin Goln, Med Fac, Ljubljana, Slovenia

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 27期

关键词：

afatinib; osimertinib; NSCLC; sequential; T790M; 1ST-LINE TREATMENT; OPEN-LABEL; T790M MUTATION; SURVIVAL-DATA; ADENOCARCINOMA; GEFITINIB; CHEMOTHERAPY; EFFICACY; TKI;

D O I：

10.2217/fon-2018-0711

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials& methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment 10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770

引用

下载

页码：2861 / 2874

页数：14

共 50 条

[41] Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Hirsh, Vera
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[42] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
Cai, Hongfu
Zhang, Longfeng
Li, Na
Chen, Shen
Zheng, Bin
Yang, Jing
Weng, Lizhu
Liu, Mao-Bai
CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
[43] Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations
Kuykendall, Andrew
Chiappori, Alberto
CANCER CONTROL, 2014, 21 (01) : 67 - 73
[44] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
Kazuo Tamura
Toshihiro Nukiwa
Akihiko Gemma
Nobuyuki Yamamoto
Masaya Mizushima
Kaori Ochai
Rie Ikeda
Hisaya Azuma
Yoichi Nakanishi
International Journal of Clinical Oncology, 2019, 24 : 917 - 926
[45] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
Tamura, Kazuo
Nukiwa, Toshihiro
Gemma, Akihiko
Yamamoto, Nobuyuki
Mizushima, Masaya
Ochai, Kaori
Ikeda, Rie
Azuma, Hisaya
Nakanishi, Yoichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
[46] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Park, Keunchil
Bennouna, Jaafar
Boyer, Michael
Hida, Toyoaki
Hirsh, Vera
Kato, Terufumi
Lug, Shun
Mok, Tony
Nakagawa, Kazuhiko
O'Byrne, Kenneth
Paz-Ares, Luis
Schuler, Martin
Sibilotru, Denis Moro
Tan, Eng-Huat
Tanaka, Hiroshi
We, Yi-Long
Yang, James C-H
Zhang, Li
Zhou, Caicun
Maerten, Angela
Tang, Wenbo
Yamamoto, Nobuyuki
LUNG CANCER, 2019, 132 : 126 - 131
[47] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
Lilenbaum, Rogerio A.
Horn, Leora A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
[48] Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience
Chu, Q.
Agha, A.
Devost, N.
Walton, R. N.
Ghosh, S.
Ho, C.
CURRENT ONCOLOGY, 2020, 27 (01) : 27 - 33
[49] The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
Bai, Hao
Xiong, Liwen
Han, Baohui
ONCOTARGETS AND THERAPY, 2017, 10 : 2335 - 2340
[50] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
Kim, Edward S.
Melosky, Barbara
Park, Keunchil
Yamamoto, Nobuyuki
Yang, James C-H
FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408

← 1 2 3 4 5 →